Chenwei Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chenwei Pan has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Yongping Chen
Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
4 shared publications Al-Ameer Wail Hussein Ahmed
Department of Infectious Disease, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
2 shared publicationsDi Chen
Department of Infectious Disease, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
2 shared publicationsJianhua Zhang
Department of Infectious Diseases and Hepatology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
2 shared publicationsJiayi Xing
Department of Infectious Diseases and Hepatology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
2 shared publicationsJie Li
Department of Infectious Diseases and Hepatology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1919392
Longitudinal hematologic decline during peginterferon alfa-2b therapy in chronic hepatitis B: clinical safety and exploratory whole-blood transcriptomics
Peginterferon-based therapy for chronic hepatitis B is known to cause leukopenia, neutropenia, and thrombocytopenia, but the relationship of early hematologic trajectories to serological response, supportive management, and whole-blood molecular signals remains uncertain. We conducted an exploratory hematologic safety-focused secondary analysis of a prospective, single-center cohort of 21 patients receiving peginterferon alfa-2b-based therapy (13 responders and 8 non-responders). WBC, ANC, and platelet counts were assessed at visits corresponding approximately to baseline, Week 5, and Week 10. Non-parametric comparisons were supplemented with effect sizes and 95% confidence intervals, and supportive-treatment timing was examined in locked sensitivity analyses. All paired Visit-1-to-Visit-3 changes were negative in both response groups, whereas responder-versus-non-responder estimates were imprecise and did not establish a response-group-specific toxicity pattern. Visit-2 WBC 9 /L occurred in 19/21 patients (90.5%; exact 95% CI: 69.6%-98.8%) and was treated as a pragmatic clinical-management context threshold rather than a discriminating transcriptomic endpoint. A post-documented oral-support-date indicator did not materially alter the fitted WBC or ANC pattern, but this non-randomized sensitivity analysis cannot estimate treatment efficacy. In the manuscript-consistent DESeq2 variance-stabilizing-transformation workflow, no unadjusted primary Hallmark or candidate-gene family met the prespecified exploratory BH-FDR q < 0.10 threshold. A reviewer-directed xCell2 sensitivity analysis showed longitudinal internal concordance between the prespecified neutrophil enrichment score and measured ANC; composition adjustment changed several pathway estimates, but no paired W0-W10 family reached q < 0.10 and unstable baseline-adjusted platelet signals did not support a specific pathway or mechanism. These small-cohort findings are exploratory, are not evidence of equivalence or mechanism, and require confirmation in larger independent cohorts.
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1919392
Open AccessLongitudinal hematologic decline during peginterferon alfa-2b therapy in chronic hepatitis B: clinical safety and exploratory whole-blood transcriptomics
Peginterferon-based therapy for chronic hepatitis B is known to cause leukopenia, neutropenia, and thrombocytopenia, but the relationship of early hematologic trajectories to serological response, supportive management, and whole-blood molecular signals remains uncertain. We conducted an exploratory hematologic safety-focused secondary analysis of a prospective, single-center cohort of 21 patients receiving peginterferon alfa-2b-based therapy (13 responders and 8 non-responders). WBC, ANC, and platelet counts were assessed at visits corresponding approximately to baseline, Week 5, and Week 10. Non-parametric comparisons were supplemented with effect sizes and 95% confidence intervals, and supportive-treatment timing was examined in locked sensitivity analyses. All paired Visit-1-to-Visit-3 changes were negative in both response groups, whereas responder-versus-non-responder estimates were imprecise and did not establish a response-group-specific toxicity pattern. Visit-2 WBC 9 /L occurred in 19/21 patients (90.5%; exact 95% CI: 69.6%-98.8%) and was treated as a pragmatic clinical-management context threshold rather than a discriminating transcriptomic endpoint. A post-documented oral-support-date indicator did not materially alter the fitted WBC or ANC pattern, but this non-randomized sensitivity analysis cannot estimate treatment efficacy. In the manuscript-consistent DESeq2 variance-stabilizing-transformation workflow, no unadjusted primary Hallmark or candidate-gene family met the prespecified exploratory BH-FDR q < 0.10 threshold. A reviewer-directed xCell2 sensitivity analysis showed longitudinal internal concordance between the prespecified neutrophil enrichment score and measured ANC; composition adjustment changed several pathway estimates, but no paired W0-W10 family reached q < 0.10 and unstable baseline-adjusted platelet signals did not support a specific pathway or mechanism. These small-cohort findings are exploratory, are not evidence of equivalence or mechanism, and require confirmation in larger independent cohorts.
- Open Access
- 22 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
AKR1B15 promotes hepatocarcinogenesis by activating the p53-PI3K-AKT-mTOR-E2F1 signaling pathway
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, with limited biomarkers available for early diagnosis and targeted therapy. AKR1B15, a lesser-studied member of the aldo-keto reductase family, shares high sequence similarity with AKR1B10, but its role in HCC remains unclear. Therefore, this study aimed to investigate the biological function of AKR1B15 in HCC and its involvement in oncogenic signaling pathways. Bioinformatic analysis of gene expression datasets and patient tissue samples was used to evaluate AKR1B15 expression and prognostic relevance. Functional assays were conducted following AKR1B15 knockdown, including CCK-8, colony formation, transwell, wound healing, flow cytometry, and xenograft models. Western blotting and immunofluorescence were employed to assess phosphorylation of key signaling molecules. AKR1B15 expression was significantly elevated in HCC tissues and associated with higher pathologic T stage and worse disease-specific survival ( P < 0.05). AKR1B15 knockdown inhibited HCC cell proliferation, invasion, and migration ( P < 0.01), and promoted apoptosis ( P < 0.001). In vivo, AKR1B15 depletion suppressed tumor growth and reduced Ki-67 expression. Mechanistically, silencing AKR1B15 decreased phosphorylation of p53 (Ser15), PI3K (Tyr458/199), AKT (Ser473), mTOR (Ser2448), and E2F1 (S364), indicating inhibition of the p53-PI3K-AKT-mTOR-E2F1 axis. AKR1B15 promotes HCC progression and is associated with activation of the p53-PI3K-AKT-mTOR-E2F1 signaling pathway. It may serve as a novel diagnostic marker and therapeutic target in hepatocellular carcinoma.
- 22 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAKR1B15 promotes hepatocarcinogenesis by activating the p53-PI3K-AKT-mTOR-E2F1 signaling pathway
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, with limited biomarkers available for early diagnosis and targeted therapy. AKR1B15, a lesser-studied member of the aldo-keto reductase family, shares high sequence similarity with AKR1B10, but its role in HCC remains unclear. Therefore, this study aimed to investigate the biological function of AKR1B15 in HCC and its involvement in oncogenic signaling pathways. Bioinformatic analysis of gene expression datasets and patient tissue samples was used to evaluate AKR1B15 expression and prognostic relevance. Functional assays were conducted following AKR1B15 knockdown, including CCK-8, colony formation, transwell, wound healing, flow cytometry, and xenograft models. Western blotting and immunofluorescence were employed to assess phosphorylation of key signaling molecules. AKR1B15 expression was significantly elevated in HCC tissues and associated with higher pathologic T stage and worse disease-specific survival ( P < 0.05). AKR1B15 knockdown inhibited HCC cell proliferation, invasion, and migration ( P < 0.01), and promoted apoptosis ( P < 0.001). In vivo, AKR1B15 depletion suppressed tumor growth and reduced Ki-67 expression. Mechanistically, silencing AKR1B15 decreased phosphorylation of p53 (Ser15), PI3K (Tyr458/199), AKT (Ser473), mTOR (Ser2448), and E2F1 (S364), indicating inhibition of the p53-PI3K-AKT-mTOR-E2F1 axis. AKR1B15 promotes HCC progression and is associated with activation of the p53-PI3K-AKT-mTOR-E2F1 signaling pathway. It may serve as a novel diagnostic marker and therapeutic target in hepatocellular carcinoma.
- Open Access
- 1 October 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-18
Integrated single-cell RNA-seq analysis reveals that EZH2 regulates the MIF-CD74 axis to modulate T cell activation and exhaustion in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a highly lethal malignancy characterized by a complex pathological mechanism involving multiple genes and progressive stages. The efficacy of targeted and immunotherapy remains limited, highlighting the urgent need for a reliable model to predict prognosis and response to immune checkpoint inhibitors (ICIs). We developed an integrated model based on genes related to autophagy, senescence, dormancy, mitochondrial function, and tumor stemness. The predictive capability of this model for HCC prognosis and ICI response was evaluated. Single-cell transcriptomic analysis and immunocompetent mouse models were further utilized to elucidate the role of model-associated genes in regulating the tumor immune microenvironment. A 16-gene integrated model was constructed using genes associated with mitochondrial function, autophagy, dormancy, stemness, and senescence. This model demonstrated robust predictive power for HCC prognosis and ICI responsiveness. Single-cell trajectory analysis revealed that EZH2 plays a crucial role in immune cell infiltration, activation, and HCC progression. Additionally, in vivo mouse models further indicated that EZH2 may regulate CD8+ T cell activation and exhaustion through the MIF-CD74 signaling pathway. The integrated model holds potential as a prognostic and predictive tool for HCC immunotherapy. EZH2 may influence CD8+ T cell activation and exhaustion via the MIF-CD74 axis, providing insights for patient stratification and potential therapeutic strategies to enhance immunotherapy efficacy.
- 1 October 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-18
Open AccessIntegrated single-cell RNA-seq analysis reveals that EZH2 regulates the MIF-CD74 axis to modulate T cell activation and exhaustion in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a highly lethal malignancy characterized by a complex pathological mechanism involving multiple genes and progressive stages. The efficacy of targeted and immunotherapy remains limited, highlighting the urgent need for a reliable model to predict prognosis and response to immune checkpoint inhibitors (ICIs). We developed an integrated model based on genes related to autophagy, senescence, dormancy, mitochondrial function, and tumor stemness. The predictive capability of this model for HCC prognosis and ICI response was evaluated. Single-cell transcriptomic analysis and immunocompetent mouse models were further utilized to elucidate the role of model-associated genes in regulating the tumor immune microenvironment. A 16-gene integrated model was constructed using genes associated with mitochondrial function, autophagy, dormancy, stemness, and senescence. This model demonstrated robust predictive power for HCC prognosis and ICI responsiveness. Single-cell trajectory analysis revealed that EZH2 plays a crucial role in immune cell infiltration, activation, and HCC progression. Additionally, in vivo mouse models further indicated that EZH2 may regulate CD8+ T cell activation and exhaustion through the MIF-CD74 signaling pathway. The integrated model holds potential as a prognostic and predictive tool for HCC immunotherapy. EZH2 may influence CD8+ T cell activation and exhaustion via the MIF-CD74 axis, providing insights for patient stratification and potential therapeutic strategies to enhance immunotherapy efficacy.
- 8 September 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 355 (Pt A) , 120574
Biejia-Ruangan enhances the efficacy of entecavir in reversing liver cirrhosis in patients with chronic HBV infection: A seven-year open-label follow-up cohort study
- 8 September 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 355 (Pt A) , 120574
Biejia-Ruangan enhances the efficacy of entecavir in reversing liver cirrhosis in patients with chronic HBV infection: A seven-year open-label follow-up cohort study
- Open Access
- 1 August 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (8) , 4662-4678
Thyroid differentiation score-related genes and prognostic model for thyroid cancer
Background: Thyroid differentiation score (TDS) reflects the differentiation degree of thyroid cancer (THCA). This study aimed to construct a TDS-related prognostic risk model for THCA and explore the potential biomarkers. Methods: Using The Cancer Genome Atlas (TCGA)-THCA dataset, overlapping differentially expressed genes (DEGs) between THCA-DEGs and TDS-DEGs were identified for functional enrichment analyses to determine their biological functions. Least absolute shrinkage and selection operator (Lasso) and Cox regression analyses were applied to construct a prognostic model. The model’s predictive performance was validated through Kaplan-Meier curves, receiver operating characteristic curves, and decision curve analyses. Gene set enrichment analysis (GSEA) was performed to explore the functional pathways. Single-cell RNA sequencing analysis was performed to further explore the role of risk genes. Results: A four-gene risk model, including ATPase secretory pathway Ca2+ transporting 2 (ATP2C2), mast cell expressed membrane protein 1 (MCEMP1), FAM111 trypsin-like peptidase B (FAM111B), and uronyl 2-sulfotransferase (UST), was established, with significant predictive value for overall survival. High expression of ATP2C2 and MCEMP1 correlated with poorer prognosis, while FAM111B and UST were protective factors. GSEA revealed the involvement of apoptosis and p53 signaling pathways with four risk genes. Additionally, UST was linked to p53 signaling pathways in CD4+ memory cells, suggesting its critical role in THCA progression. Conclusions: The TDS-related gene risk model demonstrates strong prognostic utility in THCA. UST may inhibit the p53 signaling pathway to activate CD4+ memory cells in THCA, highlighting its potential as a therapeutic target.
- 1 August 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (8) , 4662-4678
Open AccessThyroid differentiation score-related genes and prognostic model for thyroid cancer
Background: Thyroid differentiation score (TDS) reflects the differentiation degree of thyroid cancer (THCA). This study aimed to construct a TDS-related prognostic risk model for THCA and explore the potential biomarkers. Methods: Using The Cancer Genome Atlas (TCGA)-THCA dataset, overlapping differentially expressed genes (DEGs) between THCA-DEGs and TDS-DEGs were identified for functional enrichment analyses to determine their biological functions. Least absolute shrinkage and selection operator (Lasso) and Cox regression analyses were applied to construct a prognostic model. The model’s predictive performance was validated through Kaplan-Meier curves, receiver operating characteristic curves, and decision curve analyses. Gene set enrichment analysis (GSEA) was performed to explore the functional pathways. Single-cell RNA sequencing analysis was performed to further explore the role of risk genes. Results: A four-gene risk model, including ATPase secretory pathway Ca2+ transporting 2 (ATP2C2), mast cell expressed membrane protein 1 (MCEMP1), FAM111 trypsin-like peptidase B (FAM111B), and uronyl 2-sulfotransferase (UST), was established, with significant predictive value for overall survival. High expression of ATP2C2 and MCEMP1 correlated with poorer prognosis, while FAM111B and UST were protective factors. GSEA revealed the involvement of apoptosis and p53 signaling pathways with four risk genes. Additionally, UST was linked to p53 signaling pathways in CD4+ memory cells, suggesting its critical role in THCA progression. Conclusions: The TDS-related gene risk model demonstrates strong prognostic utility in THCA. UST may inhibit the p53 signaling pathway to activate CD4+ memory cells in THCA, highlighting its potential as a therapeutic target.
- Open Access
- 13 October 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-7
Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis
Background: The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was still in debate.Methods: We studied patients treated with NAs and PegIFN-2b at our institution from November 2019 to January 2022. Logistic regression identified independent factors influencing clinical cure. The predictive accuracy of the formula was assessed using the Receiver operating characteristic (ROC) curve at different time points (before therapy, 12 weeks, and 24 weeks into treatment).Results: A total of 120 patients were enrolled in the final analysis. Among the cohort of patients under study, 71 (59.1%) patients had clinical cure while 49 (40.9%) patients did not. Hepatitis B surface antigen (HBsAg) at baseline and age were the powerful variables predicting the clearance of HBsAg. The area under the ROC (AUC) was 0.907 for pre-treatment predictive model, 0.958 for 12-week predictive model and 0.747 for 24-week predictive model.Conclusion: This study provided predictive formulas for clinical cure, offering valuable insights for CHB treatment. PegIFN and NAs exhibited efficacy. Future research that explores additional factors, such as HBV genotype, in a larger cohort study is needed.
- 13 October 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-7
Open AccessPredicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis
Background: The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was still in debate.Methods: We studied patients treated with NAs and PegIFN-2b at our institution from November 2019 to January 2022. Logistic regression identified independent factors influencing clinical cure. The predictive accuracy of the formula was assessed using the Receiver operating characteristic (ROC) curve at different time points (before therapy, 12 weeks, and 24 weeks into treatment).Results: A total of 120 patients were enrolled in the final analysis. Among the cohort of patients under study, 71 (59.1%) patients had clinical cure while 49 (40.9%) patients did not. Hepatitis B surface antigen (HBsAg) at baseline and age were the powerful variables predicting the clearance of HBsAg. The area under the ROC (AUC) was 0.907 for pre-treatment predictive model, 0.958 for 12-week predictive model and 0.747 for 24-week predictive model.Conclusion: This study provided predictive formulas for clinical cure, offering valuable insights for CHB treatment. PegIFN and NAs exhibited efficacy. Future research that explores additional factors, such as HBV genotype, in a larger cohort study is needed.
- Open Access
- 25 October 2022
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (22) , 5690-5701
Polyguanine alleviated autoimmune hepatitis through regulation of macrophage receptor with collagenous structure and TLR4‐TRIF‐NF‐κB signalling
Autoimmune hepatitis (AIH) is a progressive and chronic inflammatory disease in the liver. MARCO is a surface receptor of macrophage involving in tissue inflammation and immune disorders. Moreover, polyguanine (PolyG) is considered to bind to macrophage receptor with collagenous structure (MARCO). However, the role of MARCO and PolyG in the development and treatment of AIH still remains unclear. Therefore, this study explores the expression of MARCO and therapeutic activity of PolyG in both S100‐induced AIH in mouse and Lipopolysaccharide (LPS)‐treated macrophage (RAW264.7 cells). Moreover, there were significant increases in inflammatory factors and MARCO, as well as decrease in I‐kappa‐B‐alpha (Ik‐B) in the liver of AIH mice and LPS‐induced cells. However, PolyG treatment significantly reversed the elevation of inflammatory cytokins, MARCO and reduction of Ik‐B. In addition, PolyG treatment could downregulate the expression of Toll‐like receptor 4 (TLR4) and TIR‐domain‐containing adaptor inducing interferon‐β (TRIF), decrease macrophage M1 polarization and increase macrophage M2 polarization. When hepatocytes were co‐cultured with different treatment of macrophages, similar expression profile of inflammatory cytokines was observed in hepatocytes. The research revealed that MARCO expression was elevated in AIH mice. PolyG treatment and inhibition of MARCO significantly reduced inflammatory cytokines expression in the liver as well as hepatocytes and macrophages. Therefore, MARCO could be a target for the treatment of AIH.
- 25 October 2022
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (22) , 5690-5701
Open AccessPolyguanine alleviated autoimmune hepatitis through regulation of macrophage receptor with collagenous structure and TLR4‐TRIF‐NF‐κB signalling
Autoimmune hepatitis (AIH) is a progressive and chronic inflammatory disease in the liver. MARCO is a surface receptor of macrophage involving in tissue inflammation and immune disorders. Moreover, polyguanine (PolyG) is considered to bind to macrophage receptor with collagenous structure (MARCO). However, the role of MARCO and PolyG in the development and treatment of AIH still remains unclear. Therefore, this study explores the expression of MARCO and therapeutic activity of PolyG in both S100‐induced AIH in mouse and Lipopolysaccharide (LPS)‐treated macrophage (RAW264.7 cells). Moreover, there were significant increases in inflammatory factors and MARCO, as well as decrease in I‐kappa‐B‐alpha (Ik‐B) in the liver of AIH mice and LPS‐induced cells. However, PolyG treatment significantly reversed the elevation of inflammatory cytokins, MARCO and reduction of Ik‐B. In addition, PolyG treatment could downregulate the expression of Toll‐like receptor 4 (TLR4) and TIR‐domain‐containing adaptor inducing interferon‐β (TRIF), decrease macrophage M1 polarization and increase macrophage M2 polarization. When hepatocytes were co‐cultured with different treatment of macrophages, similar expression profile of inflammatory cytokines was observed in hepatocytes. The research revealed that MARCO expression was elevated in AIH mice. PolyG treatment and inhibition of MARCO significantly reduced inflammatory cytokines expression in the liver as well as hepatocytes and macrophages. Therefore, MARCO could be a target for the treatment of AIH.
- 1 September 2006
- Vol. 14 (9) , 692-4
[Effect of TGFbeta1 vaccine on the expression of MMP-2 and TIMP-2 in rats with liver fibrosis].
- 1 September 2006
- Vol. 14 (9) , 692-4
[Effect of TGFbeta1 vaccine on the expression of MMP-2 and TIMP-2 in rats with liver fibrosis].